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Aspergillus fumigatus is a human opportunistic fungal
pathogen whose cell wall protects it from the extracellular
environment including host defenses. Chitin, an essential
component of the fungal cell wall, is synthesized from
UDP-GlcNAc produced in the hexosamine biosynthetic path-
way. As this pathway is critical for fungal cell wall integrity,
the hexosamine biosynthesis enzymes represent potential
targets of antifungal drugs. Here, we provide genetic and
chemical evidence that glucosamine 6-phosphate N-acetyl-
transferase (Gna1), a key enzyme in this pathway, is an
exploitable antifungal drug target. GNA1 deletion resulted in
loss of fungal viability and disruption of the cell wall, pheno-
types that could be rescued by exogenous GlcNAc, the prod-
uct of the Gna1 enzyme. In a murine model of aspergillosis,
the gna1 mutant strain exhibited attenuated virulence.
Using a fragment-based approach, we discovered a small het-
erocyclic scaffold that binds proximal to the Gna1 active site
and can be optimized to a selective submicromolar binder.
Taken together, we have provided genetic, structural, and
chemical evidence that Gna1 is an antifungal target in
A. fumigatus.
Aspergillus spp., Candida spp., and Cryptococcus spp. are
opportunistic human pathogens that together account for most
global invasive fungal infections. Considered a significant and
growing challenge to human health (1, 2), infections attributa-
ble to Aspergillus fumigatus are a significant cause of morbidity
and mortality in an ever-expanding group of patients. For
patients undergoing hematopoietic stem cell transplantation
and in particular allogeneic grafts, invasive aspergillosis is an
important cause of pulmonary-related mortality (3). Chronic
and allergic forms are rarely life threatening, however, they are
estimated to have global burdens of 1.2 million and 4.8 mil-
lion people, respectively (4, 5). Moreover, they may affect
patients with an intact immune system but have other medical
co-morbidities, placing them at a higher risk of fungal sensiti-
zation and subsequent allergic disease. A recent phenomenon
in both immunosuppressed and immunocompetent individu-
als is post-influenza aspergillosis in the intensive care unit (6).
As both fungi and mammals are eukaryotes, antifungal drug
development faces the fundamental challenge of selective tox-
icity. Structures that are unique to fungi or that bear exploitable
dissimilarities, such as the cell membrane and the cell wall, are
targeted by the polyenes (7), azoles (8), and echinocandins (9),
respectively. Together with flucytosine (10), they represent the
only antifungal classes clinically licensed for the prevention and
treatment of aspergillosis (3) and offer limited degrees of effi-
caciousness through a restricted spectrum of cellular targets,
poor clinical and physicochemical properties, and rising rates
of drug resistance (11), particularly exacerbated through exten-
sive agricultural overuse of antifungal azoles (2, 12). A lack of
innovation, investment, and infrastructure in pharmaceutical
antifungal research has been cited for the dearth of preclinical
candidates despite a global market worth in excess of U.S. $6
billion (13). Traditionally, antifungal agents were discovered by
screening large libraries of natural products or synthetic small
molecules for their fungistatic and, preferably, fungicidal prop-
erties (14). The polyenes and echinocandins were both derived
from natural product screening. Unfortunately, many subse-
quent screens rediscovered the same basic chemical scaffolds
(14). The antifungal pipeline has displayed modest progression
(15), with only a single new antifungal class currently undergo-
ing late-stage clinical trials (Phase IIb, NCT03583164; RRID:
SCR_002309). Although the introduction of additional azoles
such as isavuconazole (16, 17) provides greater options to
reduce side effects and simplify dosing regimens, the develop-
ment of resistance is not adequately addressed by new members
of this widely used class (18).
A major characteristic feature of fungi is the presence of a
highly ordered carbohydrate cell wall that provides protection
against chemical and mechanical stresses. The cell wall is a
dynamic, interlaced, and only partially defined polysaccharide
structure that is essential for survival (19) and is considered an
attractive source of novel antifungal targets because of its
absence in humans. The A. fumigatus cell wall predominantly
consists of a central core of fibrils composed of branched -1,3
glucan crosslinked to chitin. Polysaccharides such as -1,3–1,4-
glucan and galactomannan are covalently bound to this com-
plex, whereas those contained in the surrounding cement
include -1–3 glucan. Cell wall biosynthesis and remodeling is
a highly organized and complex process, although many of the
key steps remain to be fully elucidated (19). Polysaccharide syn-
thesis of -1,3 glucan and chitin occur at the fungal cell mem-
brane using intracellular sugar nucleotide donors as substrates.
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Chitin is an integral structural component of the cell wall in
A. fumigatus, contributing to rigidity, and consists of a linear
polymer of (1– 4)–linked N-acetyl-D-glucosamine (GlcNAc).
Chitin synthesis remains an attractive drug target; however,
targeting the entire chitin synthase family is not a viable option
because of predicted differences in structure and the mem-
brane-bound location of the eight proteins (20).
An alternative target to chitin synthases is biosynthesis of
the sugar nucleotide substrate UDP-GlcNAc that is also uti-
lized for the synthesis of GPI anchors and N- and O-linked
glycans (21). Four highly conserved enzymes in UDP-GlcNAc
biosynthesis form the hexosamine biosynthetic pathway
(22), which is believed to represent the only endogenous
source of UDP-GlcNAc within fungal cells (23). Approxi-
mately 2–5% of glucose that enters the cell is directed into
this pathway where it is phosphorylated to glucose-6-phos-
phate (Glc-6P) and subsequently converted to fructose-6-
phosphate (Fruc-6P). Four enzymes catalyze the remaining
steps of this pathway. Glucosamine-6-phosphate synthase
(Gfa1) converts Fruc-6P to glucosamine-6-phosphate (GlcN-6P).
This undergoes acetylation by glucosamine-6-phosphate N-ace-
tyltransferase (Gna1) to GlcNAc-6-phosphate (GlcNAc-6P). The
next step involves isomerization by phospho-acetyl-glucosamine
mutase (Agm1) to yield GlcNAc-1-phosphate (GlcNAc-1P)
before uridylation by GlcNAc-1P-uridyltransferase (Uap1) to pro-
duce UDP-GlcNAc. This pathway is highly regulated in filamen-
tous fungi, yeast, and higher eukaryotes (23). Three of the enzymes
(Gfa1, Agm1, and Uap1) have been genetically validated in
A. fumigatus as essential for growth under in vitro laboratory con-
ditions (24–26).
Gna1 (EC 2.3.1.4) is a member of the Gcn5-related N-acetyl-
transferase (GNAT) superfamily and is present in yeast such as
Candida spp. (e.g. Candida albicans, Candida glabrata, and
Candida auris) and Saccharomyces cerevisiae. Genetic studies
in S. cerevisiae have demonstrated that deletion of GNA1 is
lethal (27). In C. albicans GNA1 is essential for in vitro viability
and attenuated virulence in a murine model of disseminated
candidiasis (28, 29). Inactivation of the murine GNA1 homo-
logue is lethal as it is implicated in mitotic membrane fusion
events and this further reinforces a critical role for this enzyme
in higher eukaryotes (30). Although evolutionarily and struc-
turally distinct from higher eukaryotic organisms, the GNA1
orthologues recently identified in parasitic protozoan apicom-
plexans have been suggested as potential therapeutic targets
(31).
To date, Gna1 in A. fumigatus is unexplored as an antifun-
gal drug target using a combination of genetic and chemical
methods. Inhibitors that chemically phenocopy a GNA1
deletion have not been reported in any organism, and the
high degree of sequence homology between eukaryotic
GNA1 family members likely precludes fungal selectivity.
Here, we report a multidisciplinary approach providing
genetic, chemical, and structural evidence supporting
A. fumigatus Gna1 as an antifungal target and describe a
fragment that exploits a previously unidentified pocket
selective for the fungal enzyme.
Results
Disruption of gna1 leads to a terminal phenotype that is
rescued by exogenous GlcNAc
To investigate the requirement for Gna1 in A. fumigatus
UDP-GlcNAc biosynthesis, we deleted GNA1 by homologous
recombination. A gna1 strain was constructed by replacing
the coding sequence with a pyrG selection marker (Fig. S1).
Transformants were evaluated by phenotypic and PCR screen-
ing before verification by Southern blotting (Fig. S1). Using a
similar approach, GNA1 (with an N-terminal His tag) was re-
introduced into the gna1 mutant (Fig. S1). Although suitable
for initial in vitro studies, it was imperative that the reconsti-
tuted strain restored pyrG prototrophy as pyrG A. fumigatus
strains are highly attenuated in murine models of aspergillosis
(32). To address this, the pyrG strain was targeted with ran-
dom integration of A. fumigatus pyrG into the chromosome to
generate a pyrG reconstituted strain (Fig. S1).
In vitro growth of A. fumigatus gna1 was completely inhib-
ited in glucose (Glc)-supplemented media and restored to com-
parable levels upon replacement of glucose with GlcNAc, the
product of the Gna1 enzyme (Fig. 1A). This demonstrates that
GNA1 is essential for viability of A. fumigatus in standard in
vitro laboratory media rich in glucose and concurs with previ-
ous work in yeast (27, 29). We considered the physiological
relevance of these Glc and GlcNAc concentrations because fail-
ure to correlate with physiological nutritional availability may
incorrectly assign a gene as essential for growth. The glucose
concentration used is 20-fold greater than the mean physiolog-
ical human blood glucose level (110 mM versus 5.5 mM) and in
lung alveoli glucose concentrations are further reduced (0.1
mM) (33). Specific human physiological levels of GlcNAc are
unspecified in the literature but regarded as low and subject to
fluctuation. We initially investigated rescue of gna1 on solid
media supplemented with Glc (0.1 mM) and a simulated range
of physiological GlcNAc concentrations, above and below pre-
viously reported levels (29) (Fig. 1A). The gna1 growth phe-
notype in the presence of low GlcNAc levels (1.5 M) was char-
acterized by a complete loss of hyphae and melanin pigment.
High GlcNAc levels (150 M, 100-fold increase) partially re-
stored hyphal development, but colonies were still strikingly
devoid of pigmentation and overall radial growth was less than
the parental and reconstituted strain. We describe these char-
acteristics as a terminal phenotype.
To dissect the interplay between exogenous Glc and GlcNAc,
we developed a checkerboard assay to assess 285 different
nutritional combinations of these to explore possible concen-
trations encountered by A. fumigatus in the human host envi-
ronment (Fig. 1B). Heat map analysis demonstrated that loss of
GNA1 is associated with a terminal phenotype defective in
conidial pigmentation and hyphal growth across a range of esti-
mated physiological concentrations.
The observed gna1 terminal phenotype is unlikely to be a
result of a Gna1 scaffolding effect as metabolic supplementa-
tion with GlcNAc is restorative, indicating that disruption of
Gna1 enzymatic function is sufficient to elicit the observed
reduction in fungal viability. Taken together, these experiments
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show that disruption of gna1 leads to a terminal phenotype that
is rescued by exogenous GlcNAc.
The gna1 strain displays a cell wall phenotype
Next, we investigated whether rescue of GNA1 with exoge-
nous GlcNAc induces a cell wall stress response. A. fumigatus
harbors cell wall integrity pathways that are activated under
conditions of stress by signaling pathways such as the mitogen
activated protein kinase cascades (34). As the terminal pheno-
type did not yield sufficient growth for comparative analyses,
this experiment was performed using a GlcNAc concentration
of 90 mM to rescue growth. At concentrations of 104 viable
conidia, the gna1 mutant displayed increased sensitivity to
agents compromising the cell wall and membrane, suggesting
the presence of cell wall defects and/or loss of membrane integ-
rity (Fig. 1A). Calcofluor White interacts with chitin, leading to
disruption of chitin polymer assembly and impairing the corre-
sponding linkages to other cell wall components (35). Increased
susceptibility to Congo Red suggests a reduction of -1,3 and
-1,6 glucans. Increased sensitivity to sodium dodecyl sulfate
(SDS) reflects a compromised membrane that may be because
of differences in the chitin layer. Finally, we investigated
whether loss of A. fumigatus GNA1 enhanced the effects glucan
synthesis inhibition by the echinocandin caspofungin (Fig. 1A).
Exposure to caspofungin induced a terminal phenotype in the
gna1 mutant (104 conidia) and was fungicidal at lower con-
centrations. This provides evidence of synergistic in vitro activ-
ity of a -glucan synthase inhibitor together with the gna1
mutant.
To probe the effects of Glc on germination, parental and
gna1 mutant germlings were examined by light microscopy
(Fig. 1C). Under conditions tested the gna1 mutant was non-
viable (Fig. 1A) and examination of the conidia demonstrated a
subset that was enlarged and highly disorganized with evidence
of multiple, rudimentary germ-tubes whose development was
prematurely arrested (Fig. 1C). Despite macroscopically com-
parable phenotypes, the gna1 mutant conidia incubated in
the presence of 90 mM GlcNAc also displayed abnormalities
compared with the parental strain (Fig. 1C). Although hyphae
were evident at 24 h, there was also evidence of conidial
Figure 1. Disruption of gna1 leads to a terminal cell wall phenotype partially rescued by GlcNAc. A, upper panel, colony morphology after 48 h incubation
following inoculation of viable A. fumigatus conidia on CM supplemented with Glc and GlcNAc (as indicated). The morphology of gna1 in the central two
images is indicative of the terminal phenotype. Lower panel, serial dilutions of viable conidia were inoculated onto solid CM (0.1 mM Glc  50 mM GlcNAc)
supplemented with SDS, Calcofluor White (CFW), Congo Red (CR), or caspofungin (CF) and incubated for 48 h. Images are representative of results obtained
from three independent experiments (n  3). B, heat map of growth after 48 h incubation (inoculum 1  103 viable conidia) in a checkerboard assay containing
combinations of Glc and GlcNAc from 0 to 50 mM (2-fold serial dilutions). The parental, gna1 mutant, and reconstituted strain were scored numerically from
1 (no growth/inoculum spot) to 7 (confluent growth with dark pigmented conidia). Each square denotes an individual condition and represents the mean
growth from three independent experiments (n  3). Black (maximum growth) to white (no growth). C, exogenous Glc arrests conidial germination and GlcNAc
rescue fails to fully restore viability of gna1. Left panel, conidia were inoculated into liquid CM containing Glc (upper) and GlcNAc (lower), incubated for up to
24 h and examined using a Leica light microscope at 40 magnification. Scale bar: 0.05 mm. C, ratio of viable conidia versus total number of conidia. Each data
point represents an individual replicate from a minimum of three independent experiments; horizontal lines represent the mean 	 S.D. (n  3). A ratio of 1
denotes no difference. ***, p 
 0.0001. D, viable conidia (1  105) were inoculated onto solid CM supplemented with Glc and GlcNAc and incubated for 16 h
(hyphae, upper panel) or 96 h (conidia, lower panel). Samples were fixed, processed, and examined using EM (upper panel, TEM; lower panel, SEM). Scale bar:
upper panel, 361 nm; lower panel, 10 m. P, parental; M, gna1 mutant; R, reconstituted A. fumigatus strains. All incubations were at 37 °C.
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enlargement and a lack of polarized hyphal growth with some
gna1 germ tubes unable to branch (Fig. 1C). We hypothesize
that this subpopulation of abnormal conidia accounts for the
significant reduction in viability of the A. fumigatus gna1
strain (Fig. 1C). GlcNAc is unable to completely rescue this
phenotype. This suggests a possible cell wall phenotype because
of reduced flux through the hexosamine biosynthetic pathway.
Defects in the cell surface architecture of the parental and
gna1 mutant strains were also revealed by both scanning elec-
tron microscopy (SEM) and transmission electron microscopy
(TEM). SEM analysis demonstrated that the gna1 mutant
grown under terminal phenotype conditions (0.1 mM Glc and
1.5 M GlcNAc) displayed conidiophore collapse (Fig. 1D). The
vesicular head was grossly abnormal with the presence of
“naked” phialides and no obvious conidia compared with the
parental strain (Fig. 1D). TEM analysis revealed a disorganized
cell wall ultrastructure for the gna1 mutant, with a less-de-
fined chitin layer and a more dispersed outer mannoprotein
layer (Fig. 1D). These data suggest that loss of GNA1 is associ-
ated with a defective and potentially more porous cell wall and
provides a molecular basis for the observed synergy with caspo-
fungin. Taken together, these data show that the gna1 strain
displays a cell wall phenotype.
GNA1 contributes to A. fumigatus pathogenicity in models of
aspergillosis
Ascertaining the physiological implications of GNA1 loss by
translating in vitro phenotypic characterizations into in vivo
infection models is an important step in providing genetic val-
idation as an antifungal target. In particular, it is critical to
determine whether in vivo GlcNAc scavenging systems could
compensate for GNA1 loss. Nonvertebrate mini-host model
systems such as the greater wax moth larvae (Galleria mello-
nella) represent a rapid initial screening strategy (36). Larval
inoculation resulted in a mean survival time of 3 days for the
parental and reconstituted strains whereas the gna1 mutant
was avirulent with a survival profile indistinguishable from the
PBS control group (Fig. 2A).
A disadvantage of G. mellonella is that it fails to represent the
natural inhalation route of Aspergillus. To recapitulate inhala-
tional acquisition of A. fumigatus and provide insight into the
physiological interplay of alveolar glucose and GlcNAc levels in
circumventing GNA1 loss, we used an established neutropenic
murine model of invasive pulmonary aspergillosis (37). A pre-
liminary study was performed using three concentrations of
viable A. fumigatus conidia and the contribution of the gna1
mutant to pathogenicity was compared with the parental and
reconstituted strains. In this experiment, the gna1 mutant was
less virulent (Fig. 2B). The median survival time was 4 days for
the parental and reconstituted strains whereas a value could not
be determined for the gna1 mutant (75% survival). This find-
ing was confirmed in a subsequent study (Fig. 2C) using doses
refined for each strain designed to induce signs of invasive
aspergillosis after 3 days post inhalation (see supporting
information). Although the mean survival times between
A. fumigatus strains are not directly comparable because of dif-
ferences in dose, there was an 83% survival rate to day 10 for
mice exposed to the lowest concentration (0.25) of the gna1
mutant strain compared with 33% and 0% for the parental and
reconstituted strains at their highest concentrations (4.00)
(see Table S2). Approximately 1 to 2 log higher concentrations
of gna1 were required to induce clinical disease (Fig. 2C).
Overall these findings suggest that a degree of metabolic
(GlcNAc) rescue of gna1 may occur in vivo. Nevertheless,
these data show that GNA1 contributes to A. fumigatus patho-
genesis in models of aspergillosis.
Discovery of small molecules that target the Gna1 dimer
interface
There are currently no selective small molecule inhibitors for
the Gna1 class of enzymes to attempt to chemically phenocopy
the genetic phenotype. Mechanistically, A. fumigatus (Af) Gna1
facilitates N-acetylation of GlcN-6P by promoting direct
nucleophilic attack at the thioester carbonyl group of the acetyl
coenzyme A (AcCoA) cofactor by the sugar-phosphate amino
group (38). Although sharing only 30% sequence identity,
Figure 2. GNA1 contributes to A. fumigatus pathogenicity in invertebrate and murine models of aspergillosis. A, G. mellonella were inoculated with 5 
105 conidia of A. fumigatus (parental, gna1 mutant, or reconstituted strains) or PBS as a vehicle control. Survival was monitored daily as evident by movement
and lack of melanization. Data are combined from four independent experiments (n  4 with a combined total of 120 larvae per group). p 
 0.0001. B,
neutropenic male CD1 mice were exposed to 1  107 A. fumigatus aerosolized conidia from the parental, gna1 mutant, and reconstituted strains in an
inhalational chamber (n  4 per group). C, neutropenic male CD1 mice were exposed to a trio of refined doses of A. fumigatus aerosolized conidia from the
parental, gna1 mutant, and reconstituted strains in an inhalational chamber (n  6 per group). A reference dose of x 1.00 was set to that observed to induce
signs of disease from day 3. Each symbol represents an individual animal. In B and C, mice were monitored for up to 10 days post infection and any mouse
showing clinical signs of disease or distress was culled immediately and death being recorded as the next day.
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structurally AfGna1 and Homo sapiens (Hs) Gna1 adopt the
same overall fold and domain architecture, with highly con-
served regions localized to the AcCoA-binding site with minor
differences in the sugar substrate– binding region. These differ-
ences are localized to amino acids involved in sugar-phosphate
group recognition, which in the fungal enzyme utilize side
chain functionality that is less polar in character (38, 39). In an
attempt to circumvent issues of high structural homology
between human and fungal Gna1, we deployed a fragment-
based approach (40) to discover small molecules that target
previously unidentified pockets that are selective for the fungal
enzyme. Bio-layer interferometry (BLI) was used to identify
Gna1 binders from a 650-compound in-house fragment library
(41–43). This produced an initial hit rate of 5.7% (Fig. S2). The
top hit (Fig. 3A, 1) displayed stoichiometric binding and high
ligand efficiency (LE  0.57 kcal mol1 NHA1 for 1), with a 6
M equilibrium dissociation constant which was confirmed by
isothermal titration calorimetry (Fig. S2).
We next used X-ray crystallography to determine the bind-
ing mode of 1. AfGna1 was co-crystallized with AcCoA and
soaked into solutions of 1. Synchrotron diffraction data to 1.6 Å
(Fig. 3, Table 1) were collected and used to solve the structure
by molecular replacement. Previous work has shown that
A. fumigatus Gna1 possesses a classic GNAT /-fold, forming
an obligate homodimer. This dimer shows extensive secondary
structure swapping with substrate and cofactor binding to the
two active sites that are formed by channels on the surface of
the enzyme, composed of amino acids from both AfGna1 mono-
mers (39). Intriguingly, electron density corresponding to frag-
ment hit 1 was observed in a pocket buried at the dimer inter-
face in the core of the enzyme, binding across a crystallographic
2-fold axis that generates the AfGna1 homodimer and the
symmetry-related molecule of fragment hit 1, visible in the
AfGna1-1 co-complex structure (Fig. 3B). This hydrophobic
pocket (400 Å3) accommodates fragment hit 1, which is posi-
tioned 8 Å from both GlcN-6P substrate– binding sites with a
histidine residue (His-127) from each monomer trapping the
fragment in a - stacking arrangement (Fig. 3B). Critically,
AfGna1 His-127 is substituted with an arginine (Arg-118) in the
human enzyme, blocking the pocket and importantly, prevent-
ing fragment binding to HsGna1 (Fig. 3B, Fig. S3), whereas His-
127 is conserved among clinically relevant fungal species (Fig.
S3). With the exception of Arg-118, the amino acids lining the
fragment-binding pocket are conserved between clinically rel-
evant fungal Gna1 orthologues and HsGna1 (Fig. S3).
To develop the fragment scaffold toward AfGna1-selective
inhibition, the binding characteristics of the fragment within
the dimer interface pocket were explored to identify the struc-
tural requirements for optimal AfGna1 binding (Fig. S2). The
staggered bi-ring system of 1 in the AfGna1-1 complex is likely
a consequence of reducing steric repulsion between the ortho-
chloro substituent of the aryl ring system and the adjacent
1,2,4-triazole (dihedral angle, ; 51°). This results in optimal
positioning of 1 to facilitate the important - stacking inter-
actions with the His-127 residues present in the pocket (Fig.
3B). It appeared essential to maintain this bi-ring arrangement
as loss or replacement of the ortho-substituent increased or
ablated binding affinity (Fig. S2).
With the ortho-chloro substituted scaffold identified, we
considered the close proximity of the glutamic acid residue
(Glu-129) that separates fragment hit 1 and the substrate-bind-
ing site from each respective AfGna1 monomer. Superposition
of AfGna1–GlcNAc-6P complex (the N-acetylated enzymatic
product of GlcN-6P; PDB ID 2VXK (89)) onto the co-complex
structure of AfGna1 with 1 illustrates the close proximity of the
Figure 3. Derivatives of a fragment screen hit selectively target an
unusual Gna1 pocket close to the active site. A, chemical structures and
binding affinities of fragment-hit (1) and derivatives (2 and 3). B, panels show-
ing the structures of apo-HsGna1 (PDB ID 2HUZ (91)) and co-complex struc-
tures of AfGna1-1, AfGna1-2, and AfGna1-3. Gna1 monomer units (cyan and
green); bound small molecules and crystallographic symmetry–related mole-
cules (yellow and transparent sticks, respectively); GlcNAc-6P (blue sticks);
Glc-6P (plum sticks); water molecules (pink spheres); hydrogen-bond interac-
tions (red dashed lines); crystallographic axis (black lines) are shown. In all co-
complex structures, small molecule electron density was observed binding
across the crystallographic 2-fold axis that generates the AfGna1 homodimer.
The symmetry-equivalent molecules of fragment hit 1, 2, and 3 are shown as
transparent sticks. In apo-HsGna1, the novel dimer interface-binding pocket is
occluded by Arg-118 residues preventing ligand binding. In AfGna1, substi-
tution of Arg-118 by His-127 facilitates - stacking with 1, 2, and 3 forming
the basis of fungal selective fragment binding. Superposition of enzymatic
product, GlcNAc-6P (PDB ID 2VXK (89)) onto co-complex structures AfGna1-1
and AfGna1-2 demonstrates the proximity of the fragment hit and derivatives
to the Glu-129 side chains and substrate binding sites. The AcCoA cofactor is
not visible from selected viewpoint. The Fo  Fc map for the bound small
molecules (fragment hit 1, 2, and 3) are shown as a mesh (gray) contoured to
2.5 	.
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Glu-129 side chains to the fragment hit 1 (3.4 Å) and to the
substrate-binding sites (8.2 Å) (Fig. 3B). Previous Gna1 studies
have indicated that orthologous glutamate residues, although
not playing a catalytic role, contribute to substrate and cofactor
binding through direct contacts and through hydrogen bond–
mediated water interactions (27, 44, 45). Indeed, our data dem-
onstrate that mutations which remove the Glu-129 carboxylate
(E129A) or substitute it with the corresponding amide (E129Q)
reduced enzymatic activity compared with WT AfGna1 (Fig.
S4). As such, we hypothesized that the close proximity of Glu-
129 residues to fragment hit 1 may offer scope to develop deriv-
atives that exploit the Glu-129 the side-chain functionality to
both improve fragment-binding affinity and elicit enzyme inhi-
bition through perturbation of Glu-129 –mediated interactions
(Fig. 3A, E129 modulation approach).
To explore the feasibility of harnessing Glu-129 fragment
proximity toward enzyme binding and inhibition, a meta-ani-
lino group was installed into the scaffold. This resulted in frag-
ment derivative 2, which displayed submicromolar affinity (0.8
M, Fig. 3A). Derivative 2 also displayed improved ligand effi-
ciency compared with fragment hit 1 as a result of this minimal
scaffold addition, resulting in a highly efficient binder (LE 
0.64 kcal mol1 NHA1 for 2). Overall, 2 maintains the impor-
tant - binding interaction observed in the AfGna1-1 com-
plex structure. As observed in the AfGna1–2 complex struc-
ture, the introduction of the meta-anilino group causes a
positional shift of 2 (32o from fragment hit 1), facilitating a
hydrogen bond interaction between 2 and the Glu-129 side
chain that likely drives the observed enhancement in binding
affinity (Fig. 3). Although derivative 2 did not show inhibition
against AfGna1 in a recombinant enzyme assay, exploiting the
proximity of the Glu-129 side chains may be a route to improv-
ing binding potency, through provision of an anchoring point
from which to introduce chemical functionality to modulate
the position or protonation state of the Glu-129 residues to
achieve inhibition.
As an alternative approach to achieving AfGna1 inhibition,
we aimed to exploit the protein tunnels that connect the dimer
interface fragment binding pocket to the substrate-binding
sites (distance of 1 to substrate-binding site  8 Å, Fig. 3).
Extension of the fragment scaffold into the active sites by tra-
versing these tunnels would effectively generate a competitive
enzyme inhibitor by blocking substrate binding at both AfGna1
active sites (Fig. 3A, bifurcation approach).
In contrast to Glu-129 modulation, the success of bifurcation
is predicated upon the ability of fragment hit 1 derivatives to
both successfully reach the buried dimer interface binding
pocket and be spatially accommodated despite the concomitant
increase in fragment molecular size, which could conceivably
hinder binding on both accounts. To test the ability of a bifur-
cated derivative of 1 to bind AfGna1, 3 was synthesized. This
bifurcated fragment introduces an N,N-diethyl alcohol moiety
into the scaffold and displays a binding affinity of the same
order as fragment hit 1 (5 M, Fig. 3A, Fig. S2). Importantly, this
illustrates that the introduction of a bifurcated modification
into the fragment scaffold is tolerated and that fragment-bind-
ing affinity is maintained and not compromised by the intro-
duction of simple linker groups. An AfGna1–3 complex struc-
ture, which additionally contains Glc-6P, indicates that 3 is
accessible to the fragment-binding site, despite narrow tunnels
linking the fragment binding pocket to the enzyme active sites
(Fig. 3B, Fig. S3). Like fragment hit 1 and 2, the important bind-
ing interactions and binding mode are maintained in the
AfGna1–3-(Glc-6P) complex structure. In addition, the hy-
droxy functionality of the N,N-diethyl alcohol moiety displaces
His-127– coordinating water molecules and interacts with the
acceptor nitrogen atoms of the His-127 side chains (Fig. 3B).
The introduction of a para-anilino anchoring point for bifurca-
tion leverages the sp2 character of the anilino-nitrogen, main-
taining the planarity necessary at the branch point for correct
N,N-diethyl alcohol orientation whereas ortho-dichloro substi-
tution positions the fragment along the 2-fold crystallographic
Table 1
Crystallographic data collection and refinement statistics
Statistics for the highest-resolution shell are shown in parentheses.
AfGna1-1-AcCoA AfGna1-2-AcCoA AfGna1-3-ACoA–(Glc-6P)
Beamline DLS-IO4–1 ESRF-ID30A-3 ESRF-ID30A-1
Resolution (Å) 56.46 (1.64–1.58) 40.32 (1.80–1.74) 58.2 (2.08–2.01)
Space group C 2 2 21 C 2 2 21 C 2 2 21
Unit cell (Å) a, b, c 67.64, 102.51, 56.62 70.21, 101.2, 56.37 70.96, 101.71, 55.91
    
 (°) 90 90 90
Total reflections 150,350 (5090) 94,486 (4877) 53,191 (2813)
Unique reflections 26,623 (2681) 20,528 (2069) 13,064 (1243)
Multiplicity 5.6 (3.8) 4.6 (4.7) 4.0 (4.2)
Completeness (%) 97 98 94.6
I/	(I) 11.8 (0.7) 16.2 (2.3) 14.5 (2.4)
Rmerge (%) 6.2 (123) 4.1 (49.0) 4.9 (57.8)
CC1⁄2 99.8 99.9 99.9
Rwork/Rfree (%) 20.0/22.7 19.0/23.5 21.1/26.4
Average B-factor (Å2) 38.0 35.7 46.6
Protein 37.90 35.48 46.25
Ligand 32.77 29.38 47.62
Solvent 47.42 42.93 54.03
No. of residues 164 165 165
No. of water molecules 108 88 45
Root mean square deviation
Bonds (Å) 0.012 0.013 0.009
Angles (°) 1.89 1.89 1.81
PDB code 6TDH 6TDG 6TDF
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axis (with a positional shift of 0.6 Å and 19o reorientation from
fragment hit 1). As a result, bifurcation vectors are identically
orientated toward both AfGna1 active sites in contrast to the
binding positions of fragment hit 1 and 2 (Fig. 3B). Moreover,
the positioning of the Glc-6P 6.2 Å from the ethyl chain linker
of 3, visible in the AfGna1–3-(Glc-6P) complex structure (Fig.
3B, Fig. S3), is suggestive of fragment-linking approaches
toward AfGna1 inhibition, albeit challenging because of the
limited size of the tunnel (46). In line with this, derivative 3 did
not show inhibition against AfGna1 in a recombinant enzyme
assay, probably because of the inability of the N,N-diethyl alco-
hol moiety to extend into and block the enzyme active sites.
Globally, the structural differences between the co-com-
plexes of AfGna1 with 1, 2, and 3 are negligible (root mean
square deviation 0.35– 0.40). However, when considering
buried protein pockets and cavities in general, such seemingly
trivial displacements may be of significance. Recent molecular
dynamics simulations and experiments have suggested that
large-scale side chain or secondary structure conformational
changes are not a prerequisite for ligand binding to buried cav-
ities but rather subtle and rapid movement of peptide structural
elements can be sufficient to facilitate ligand ingress and egress
(47–50). Although beyond the scope of this work, we speculate
that the effects of any subtle movement of structural elements
may propagate within AfGna1 and be important for ligand-
binding dynamics to the unusual buried dimer interface pocket.
Taken together, we have discovered small molecules that target
a fungal-specific binding hotspot at the Gna1 dimer interface,
providing a scaffold for the development of Gna1 inhibitors
based on these Gna1 binders.
Discussion
The current clinical management of invasive fungal infec-
tions is multifaceted, and as a consequence of limited antifungal
pipeline progression, clinicians must preserve the finite num-
ber of agents available to manage infection (51). Recent decades
witnessed an exodus of research and development into antifun-
gal drug discovery by the pharmaceutical industry resulting in
very few agents with novel mechanisms of action undergoing
clinical trials. Clinical need prevails, despite optimal antifungal
therapy, mortality rates remain around 50% although patient
co-morbidities also contribute (1). In response, a multidisci-
plinary approach to develop new targets has been advocated
(52).
Successful identification and validation of novel and ligand-
able targets is critical to the progression of the antifungal pipe-
line but the current shortage of unique targets combined with
the intrinsic therapeutic hurdles introduced by the similarities
of fungal and human enzymes only serves to complicate an
already underappreciated and growing medical problem (1, 2,
53). An attractive antifungal target is the cell wall, a structure
unique to fungi and essential for survival. The sugar polymers
constituting the cell wall are all synthesized from sugar nucle-
otide precursors. Here, we used a multidisciplinary approach
focused on an essential step in the biosynthesis of the sugar
nucleotide UDP-GlcNAc, the precursor of cell wall chitin, as a
target against A. fumigatus. Cell wall chitin has long been pro-
posed as an antifungal target. The nikkomycins and polyoxins
are substrate analogues of UDP-GlcNAc and inhibit chitin syn-
thesis in vitro with a predilection for CHS-A but fail in vivo
primarily because of resistance in chitin synthase isoenzymes
(54 –56). Our approach circumvents this failure by targeting
Gna1, a GNAT-family enzyme with no isoforms. Inhibitors tar-
geting other GNAT family members are known in the literature
(57, 58) with bisubstrate inhibitors, molecules incorporating
tethered mimics of both substrate and cofactor, offering
improved selectivity profiles compared with alternative app-
roaches but harboring nonideal pharmacokinetic properties
(59 –63). However, such an approach is unlikely to offer robust
selectivity in the case of Gna1 because of the high structural
homology between fungal and human enzyme.
Previous failings in target-based drug discovery derive from
an inadequate initial assessment of a molecular target in terms
of physiological function (64). Although GNA1 was shown to be
essential for in vitro growth in S. cerevisiae and C. albicans (27,
29), intrinsic differences in gene function across fungi because
of diverging biological and physiological functions, genetic
redundancies, or scavenging pathways precludes predictions.
Essentiality in yeasts does not automatically correlate in
A. fumigatus and therefore this was experimentally validated to
justify any potential investment in future inhibitor develop-
ment. We demonstrated that genetic disruption of A. fumigatus
GNA1 results in a terminal phenotype under simulated physi-
ological Glc and GlcNAc concentrations. This is further sup-
ported by our in vivo study using a neutropenic murine model
of invasive aspergillosis with inhalation of A. fumigatus gna1
100-fold less pathogenic than control strains. However, con-
tributions to the observed gna1 terminal phenotype from dis-
ruption to GPI anchor biosynthesis and N- and O-linked glyco-
sylation cannot be excluded.
Although the finding corroborates previous work (29), we
speculate that earlier in vitro studies were not sufficiently
robust to detect physiologically relevant nutritional rescue
strategies because if a gene were genuinely essential it would
result in avirulence rather than attenuation. Gene deletion
strategies incorporating nutritional rescue do not permit differ-
ent levels of GNA1 expression to be directly investigated. Alter-
ing the levels of extracellular GlcNAc reflects the ability of
A. fumigatus to induce salvage pathways.
Synergy between cell wall active agents is increasingly seen as
an attractive option for antifungal treatment (65). This is exem-
plified in vitro in A. fumigatus by the synergy between nikko-
mycin and the echinocandins (66). At present the echinocan-
dins are advocated as salvage therapy in invasive aspergillosis in
part because of their fungistatic activity (67). We show that
A. fumigatus gna1 combined with caspofungin has a fungici-
dal effect on in vitro growth completely abolishing not only the
terminal phenotype but also growth under maximal GlcNAc
rescue. This provides further evidence that combining a -glu-
can synthase inhibitor together with chitin inhibition is syner-
gistic in vitro. A GNA1 inhibitor could enhance the efficacy of
the echinocandins and offer additional treatment modalities
potentially as a resistance-sparing agent. In terms of biological
importance, Gna1 is an attractive antifungal target.
In addition to our genetic validation of Gna1, we sought to
identify compounds that would chemically phenocopy the bio-
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logical phenotype. The inherent difficulty in leveraging inhibi-
tor potency and selectivity between high-homology enzyme
families among higher eukaryotic organisms is a challenging
problem to fully resolve. This applies to Gna1 where deletion in
A. fumigatus yields a terminal phenotype, but deletion of the
murine orthologue leads to developmental phenotypes (68).
We pursued a fragment-based approach to overcome this chal-
lenge by discovering a previously unidentified fungal selective
pocket within AfGna1, positioned on the 2-fold axis generating
the Gna1 biological homodimer. Crucially, this pocket is absent
in the human orthologue, where it is occupied by larger side
chains (arginines versus histidines in the fungal enzyme).
Our data show that fragment derivatives can recapitulate
binding to this unusual fragment anchoring site, and rational
design targeting this pocket allows the development of micro-
molar binders that do not target the human enzyme. Although
not yet displaying AfGna1 inhibitory activity at high micromo-
lar concentrations, the opportunities toward fungal-selective
AfGna1 inhibition opened up by the discovery of fragments
binding at this fungal-selective binding pocket is promising.
Moreover, with the exception of Arg-118, the amino acids
that constitute the interface binding pocket are well-conserved
between clinically relevant fungal Gna1 orthologues and
HsGna1. Although sequence alignments have limited predic-
tive capacity in determining the structural context of the inter-
face pocket and its ligandability, this high degree of conserva-
tion warrants further structural and chemical exploration. This
binding pocket may offer a ligandable handle against other fun-
gal Gna1 orthologues, in particular, C. auris, which recently
became the first fungal species listed as an urgent drug-resistant
threat (11).
Identifying and pursuing novel avenues for inhibitor devel-
opment to overcome organism selectivity barriers is critical to
reversing the dearth in the antifungal pipeline, as is the timely
identification and validation of unusual and novel targets,
exemplified here by Gna1.
The work reported here also serves to further exemplify the
ability of fragment-based screening to uncover unique and oth-
erwise unforeseen avenues toward enzyme inhibition through
the discovery of novel binding sites. Successful fragment cam-
paigns that provide the foundation to potent inhibitors com-
monly begin with fragments that display no intrinsic enzymatic
inhibitory activity (69). The fact that fragment hit 1 and deriv-
atives (2 and 3) display a stable binding mode is often an impor-
tant prerequisite to subsequent successful fragment develop-
ment campaigns (70). Moreover, although small molecule
therapeutics that bind to protein interfaces are uncommon,
such approaches have been successfully utilized in structure-
based design campaigns to inhibit enzyme targets. For example,
HIV-1 and HIV-2 protease inhibitors, such as darunavir, bind
to a cavity at the protein dimer interface located adjacent to the
enzyme active site, forming contacts to the interface cavity and
inhibiting enzymatic activity through hydrogen bonding to cat-
alytically important D25 carboxylate side chains of both prote-
ase monomers thereby competitively inhibiting viral polypep-
tide access (71–73).
The AfGna1–3-(Glc-6P) complex structure offers a glimpse
at potential avenues of inhibition via a combination of bifurca-
tion and fragment-linking approaches. Although a rare and
challenging form of fragment development, successful frag-
ment-linking campaigns ideally utilize the conjugation of frag-
ment pairs with contrasting hydrophobic and polar ligand-
protein– binding characteristics (46). Such characteristics are
exemplified herein with fragment hit 1 and the sugar (or pseu-
dosugar) substrate and therefore provide an incentive to fur-
ther explore this approach. In parallel, exploring potential
routes toward Glu-129 modulation of substrate binding has led
to the synthesis of a submicromolar fragment binder and a key
chemical scaffold which can now be further explored and mod-
ified to elicit the desired inhibitory response.
In summary, we have provided genetic validation of AfGna1
as an antifungal target and have discovered small molecules
that target the Gna1 dimer interface, providing a platform for
generating inhibitors of the enzyme. As demonstrated, our
multidisciplinary approach, incorporating both genetic and
chemical target assessment, is critical in determining target fea-
sibility. Such approaches are not limited to fungal pathogens
and are applicable to other infectious agents and are of partic-
ular relevance when considering targets with high sequence
and structural homology to human enzymes.
Experimental procedures
Ethics statement
All animal experiments were performed by Evotec Ltd (UK)
under UK Home Office License 40/3644 and ethically approved
by The University of Manchester Standing Committee.
Strains, culture medium, and solutions
The genetic lineage and nutritional growth requirements of
all strains used and generated in this work are provided in Table
S1. Further details are provided in the supporting information.
Generation of A. fumigatus gna1 mutant
To delete GNA1, construct pgna1pyrG was designed to
replace the entire 644-bp coding region of GNA1 with the
URA-blaster (also called the pyrG blaster) as a reusable selec-
tion marker by homologous recombination (74) (Fig. S1). Refer
to the supporting information for all PCR primer sequences
used in this work. The supporting information contains details
of the experimental process including protoplast transforma-
tion, phenotypic screening, PCR screening, and Southern blot
verification (Fig. S1) of A. fumigatus gna1.
Generation of an A. fumigatus GNA16H::pyrG
reconstituted strain
A construct pGNA16H was designed to replace the entire
URA-blaster (8.3 kb) in the gna1 mutant with the native
GNA1 sequence by homologous recombination (Fig. S1).
Experimental procedures culminating in Southern blot veri-
fication followed those for generation of the gna1 mutant (see
Table S1 and supporting information). To permit in vivo appli-
cations by restoring uridine and uracil autotrophy, the recon-
stituted strain (GNA16H::pyrG-) was complemented with
pyrG by random integration. Primers were used to amplify a 1.9
kb portion of the A. fumigatus pyrG gene (75) from pXDRFP4
(76). Refer to supporting information for further details.
Targeting a critical step in fungal hexosamine biosynthesis













In vitro phenotypic analysis of A. fumigatus gna1 mutant
An agar dilution method was used to investigate in vitro
growth in the presence of different concentrations of glucose
and GlcNAc. Complete medium (CM) containing 90 mM, 150
M, and 1.5 M GlcNAc was supplemented with 0.1 mM glucose
(Glc). CM supplemented with 50 mM Glc and 0 mM GlcNAc
was a gna1 negative growth control. For preliminary evalua-
tion of growth characteristics under the above conditions,
suspensions containing serial dilutions of conidia (5 l, 1 
106  1  103) from the respective A. fumigatus strains were
inoculated on solid medium and incubated at 37 °C for 48 h. To
further assess the interaction between Glc and GlcNAc on
growth, an agar microdilution method (77) was modified using
flat-bottomed 96-well plates to generate a checkerboard assay.
This enabled simultaneous testing of 285 different combina-
tions of Glc and GlcNAc (final concentration range 0 mM to 50
mM, 2-fold serial dilutions) in a 200 l final volume (180 l of
non-glucose CM agar and 10 l each of Glc and GlcNAc). Each
well represented a different growth condition and was inocu-
lated with A. fumigatus viable conidia (1  103) and incubated
at 37 °C for 48 h. Wells were scored independently by two
unblinded investigators using a numerical code (1, no growth/
inoculum spotting to 7, growth equivalent to positive control)
to obtain an average score per condition. Scores were converted
to colors generating a growth heat map (Excel, Microsoft).
Germination was examined by inoculating liquid medium
(20 ml, CM 110 mM Glc and CM 0.1 mM Glc  90 mM GlcNAc)
with conidia (1  105) and incubating in a Petri dish containing
glass coverslips. At specified time points (5, 8, 12, and 24 h), the
coverslips were removed, washed, and fixed (2 ml, 3.7% para-
formaldehyde, 20 min). Coverslips were mounted onto glass
slides and examined using a light microscope (Leica ICC50 HD,
40 objective lens magnification).
To examine the response of the A. fumigatus gna1 mutant
to cell wall perturbing agents, suspensions of conidiophores (5
l, 1  106  1  102) were inoculated onto solid 0.1 mM Glc
CM  50 mM GlcNAc in the presence of Calcofluor White,
Congo Red, SDS (25–100 g/ml), and caspofungin (0.0625 - 0.5
g/ml). Following incubation (48 h), plates were examined. The
experiment was performed three times. For analysis of cell wall
architecture, conidia and mycelia were grown on solid medium,
fixed, processed, and examined using transmission and scan-
ning EM. Refer to supporting information for further details.
A. fumigatus gna1 infection models
Greater wax moth larvae, G. mellonella (Livefoods Direct,
Sheffield, UK), were used as an infection model (36, 78, 79).
Larvae were maintained at room temperature in wood shavings
in the dark (80) and those in the sixth instar measuring 2.0 cm in
length (250 mg) were randomly assigned into groups. The
A. fumigatus parental, gna1, and reconstituted strains were
inoculated into the hind proleg of larvae (n  30 per group) as a
10 l PBS suspension of 5  105 resting conidia. Negative con-
trols were inoculated with PBS only. Larvae were protected
from light, incubated at 37 °C, and examined at 24 h intervals.
Mortality, defined by lack of movement in response to stimuli
and discoloration (melanization) of the cuticle, was scored for 6
days.
An inhalational neutropenic murine model of invasive asper-
gillosis (37, 81) was performed by Evotec Ltd (UK) (see “Ethics
statement”). As this was an initial proof of concept study and
because of insufficient published literature using the parental
strain in this particular murine model, group size by power
analyses were unable to be performed for statistical differences
between strains. Sharing the data generated in this study will
inform future power calculations.
Male CD1 mice (Charles River, UK) weighing 23–26 g were
used for all experiments and allowed to acclimatize for at least 7
days. Mice were randomly assigned to groups and housed in
sterilized individually ventilated cages with HEPA filtered ster-
ile air and sterile aspen chip bedding (changed every 3– 4 days).
Food and water were provided ad libitum. The room tempera-
ture was 22 °C (	1 °C) with a relative humidity of 60% and
maximum background noise of 56 dB. Mice were exposed to
12-h light/dark cycles.
Mice were rendered neutropenic with intraperitoneal cyclo-
phosphamide (250 mg/kg on day 2 relative to infection, and
200 mg/kg on day 3) and subcutaneous cortisone acetate (200
mg/kg on day 2 and day 3). To generate conidial suspen-
sions of the target inoculum (Table S2) for inhalational inocu-
lation (infection) of mice, A. fumigatus parental, gna1, and
reconstituted strains were prepared according to a National
Institutes of Health (NIH) standard operating procedure (82)
with nutritional requirements as per Table S1. Viable cell
counts were performed on serially diluted aliquots of each
conidial suspension.
Each cage was randomly assigned to a study group and
infected by an inhalation chamber system (37). On the day of
infection, mice (n  4 per group for experiment 1; n  6 per
group for experiment 2) were exposed for 1 h to 12 ml of PBS
containing A. fumigatus conidia aerosolized via a Micro Mist®
nebulizer (Teleflex Medical, Kernen, Germany) in an acrylic
chamber. Enrofloxacin (50 ppm, 0.2 ml/water bag) was admin-
istered from day 3 to day 10 to prevent bacterial infection.
Mice were weighed and monitored at least daily and the study
refined using surrogate markers for invasive pulmonary asper-
gillosis. Any mouse with signs of illness and distress (see next
paragraph) were culled immediately (terminal anesthesia or
cervical dislocation) and death recorded as being the next day.
A scoring system was used based on the following parame-
ters: weight loss; hypothermia less than 32 °C; appearance
(hunching, poor coat condition); clinical signs: respiration
(noisy labored breathing); tremors/convulsions; unprovoked
behavior (little peer interaction); and provoked behavior (sub-
dued when stimulated).
Statistical analyses
Biological experiments were performed at least three inde-
pendent times with the exception of EM. Statistical analyses
were carried out using GraphPad Prism (v5.0b). Data are
expressed as the mean 	 S.D. (Fig. 1C). To compare more than
two groups, one-way ANOVA test with Bonferroni’s multiple
comparison test was used (Fig. 1C). For comparison of survival
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curves, the Kaplan-Meier Log-Rank (Mantel-Cox) Test was
performed (Fig. 2A only).
AfGna1 protein expression and purification
AfGna1 was purified as described earlier (39). Briefly, the
sequence encoding the protein was inserted into a
pGEX6P-1 vector for expression of a GST tagged fusion that
contains PreScission protease cleavage site. For protein
expression, the plasmid was transformed into Escherichia
coli BL21(DE3) pLysS. Cell cultures were grown to an A600 of
0.8 and expression was initiated by the addition of 250 M
isopropyl 1-thio--D-galactopyranoside at 17 °C. The cul-
tures were then allowed to grow for a further 16 h before
harvesting by centrifugation. After lysis, affinity chromatog-
raphy and GST tag cleavage, eluted protein was concen-
trated and further purified by size exclusion chromatogra-
phy using a Superdex 75, 26/60 column. Corresponding
fractions confirmed by SDS-PAGE were pooled concen-
trated, flash frozen in liquid nitrogen, and stored at 80 °C.
AfGna1 fragment screen and binding affinity measurements
To identify a potential fragment binder of AfGna1, the frag-
ment library of the University of Dundee Drug Discovery Unit
(DDU) comprising of 652 structurally diverse compounds was
screened using BLI (41–43). BLI experiments were performed
on an Octet Red 384 system (Forte Bio, U.S.A.) using super
streptavidin (SSA) biosensors and biotinyated-AfGna1. Pri-
mary hits identified from initial screening were defined as frag-
ments with a response rate greater than three robust standard
deviation units above the median. Confirmation of fragment hit
binding was performed with a follow-up concentration dose-
response series. Binding isotherms were fitted and visualized
using Octet software (Forte Bio, U.S.A.) to derive dissociation
constants (Kd). Refer to supporting information for further
experimental details.
AfGna1 crystallography
AfGna1 crystallization was carried out as described earlier
(39). Crystallization was manually performed using a sitting
drop approach by combining protein solution previously incu-
bated with AcCoA for 2 h on ice with reservoir solution in a 1:1
ratio and equilibrated against 60 l reservoir solution. AfGna1
crystals resembling bipyramidal or bar shape were generally
observed after 72 h incubation at 20 °C.
For fragment soaking, a soaking solution for each confirmed
fragment hit was prepared by combining a fragment DMSO
stock solution (50 –200 mM) with crystallization reservoir solu-
tion. After incubation (1 h to overnight) at 20 °C, crystals were
transferred to a cryoprotectant using a nylon loop, immersed
for 10 s and flash frozen in liquid nitrogen.
Diffraction data were collected at the European Synchrotron
Radiation Facility (ESRF), Grenoble (France) and the Diamond
Light Source, Oxford (UK). The diffraction data were automat-
ically processed and scaled by xia2 (83). An initial AfGna1-1
complex was solved by molecular replacement using MOLREP
(84) using AfGna1 apo structure (PDB ID 2VEZ (90)) as a search
molecule. Refinement was done using REFMAC5 (85) and
model building with Coot (86). Well-defined electron density
for fragment hit 1 was evident at the dimer interface. An apo
version of this new model served as a search molecule for the
determination of subsequent complexes by molecular replace-
ment. Where appropriate, ARP/wARP (87) was used to par-
tially build the model before further refinement. PRODRG (88)
was used to generate coordinates and topologies of the com-
pounds (ligands). Ligands were not included until their confor-
mations were completely defined by unbiased 	A-weighted
Fo  Fc, calc electron density maps.
Chemical synthesis of fragment derivatives
2-chloro-3-(1,2,4-triazol-3-yl)aniline, compound 2—3-ami-
no-2-benzoic acid (0.5 g, 2.90 mmol) was dissolved in dichloro-
methane/N,N-dimethylformamide (7 ml:2 ml). To the solution
was added N,N-diisopropylethylamine (1.5 ml, 8.70 mmol),
1-hydroxybenzotriazole hydrate (470 mg, 3.48 mmol), and
N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochlo-
ride (667 mg, 3.48 mmol). The solution was stirred at room
temperature under argon over 20 min, ensuring that all solid
material had dissolved. Ammonium hydroxide solution (25%,
0.35 ml) was added dropwise to the stirring solution, forming a
pale yellow suspension which was then left overnight to stir.
After aqueous workup (5–10 ml ddH2O), extraction with
ethyl acetate (4  15 ml), and drying over sodium sulfate, the
crude material (440 mg) was concentrated and rapidly puri-
fied over a silica plug (ethyl acetate 3 ethyl acetate/MeOH).
Eluted fractions were analyzed by LC-MS, confirming product
formation, and fractions containing the desired intermediate
amide product were combined (320 mg, 64% yield). Without
further purification, the intermediate amide (314 mg, 1.84
mmol) was dissolved in N,N-dimethylformamide dimethyl
acetal (6 ml) and was refluxed, under argon, at 115 °C for 15 h.
After refluxing, the solution was cooled and evaporated to dry-
ness in vacuo. In a separate receptacle, 50 – 60% hydrazine
hydrate solution (150 l) was added slowly (dropwise) to acetic
acid (9 ml). This solution was then rapidly transferred to the
dried intermediate and refluxed at 95 °C for 7 h. After reflux,
the solution was cooled and evaporated to dryness in vacuo. The
crude material was dry loaded onto silica and was directly puri-
fied by Flash Chromatography (heptane/ethyl acetate3 ethyl
acetate3 ethyl acetate/MeOH). Eluted fractions were analyzed
by LC-MS, appropriately combined, and evaporated to dryness
and resulted in an off-white solid (post-lyophilization from 50%
acetonitrile and ddH2O) (52 mg, 14% yield, Rf 0.76, ethyl ace-
tate). Overall, 9% yield over two steps: 1H NMR (500 MHz,
MeOH-D4):   8.57 (s, 1 H), 7.21 (dd, J  7.6 Hz, 7.6 Hz, 1 H),
7.06 (dd, J  8.1 Hz, 1.6 Hz, 1H), 7.01 (dd, J  7.5 Hz, 1.6 Hz,
1H). 13C NMR (101 MHz, MeOH-D4):   156.64, 147.33,
145.86, 128.61, 125.90, 121.43, 119.22, 118.60. HRMS-TOF:
Theo. m/z 195.0432; obs. m/z 195.0428; [MH], C8H8ClN4.
2,2-((3,5-dichloro-4-(1,2,4-triazol-3-yl)phenyl)azanediyl)-
bis(ethan-1-ol), compound 3—2,6-dichloro-4-nitrobenzamide
(1 g, 4.25 mmol) was dissolved in ethanol (12 ml) followed by
the addition of tin (II) chloride dihydrate (4.8 mg, 21.30 mmol).
The resulting solution was refluxed at 70 °C overnight at which
point the solution was cooled, poured into ice water (50 ml),
and pH adjusted (to pH 8 –9) using 4N aqueous sodium
hydroxide, where it was allowed to stir for 30 min. The resulting
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solid was removed by filtering over celite and the aqueous fil-
trate was then extensively extracted with ethyl acetate (6  25
ml). The organic phases were combined, dried over sodium
sulfate, and evaporated to dryness in vacuo, resulting in an off-
white solid (intermediate aniline) which was used without fur-
ther purification (72% yield).
The intermediate aniline (250 mg, 1.22 mmol) was dissolved
in acetic acid (2.5 ml), followed by the addition of 3 M ethylene
oxide–THF solution (2.5 ml). The resulting solution was stirred
at room temperature for 24 h at which point the solvent was
evaporated to near dryness in vacuuo. The crude material was
dry loaded onto silica and was directly purified by Flash Chro-
matography (ethyl acetate 3 ethyl acetate/MeOH). Eluted
fractions were analyzed by LC-MS, appropriately combined
and evaporated to dryness, resulting in a mixture of unreacted
starting material, N- and N,N-ethyl alcohol products. The reac-
tion and subsequent FLASH purification were then repeated
using the combined unreacted starting material and mono-
functionalized product to improve the conversion to the N,N-
ethyl alcohol product (145 mg, 40% yield).
The N,N-ethyl alcohol product (100 mg, 0.34 mmol) was dis-
solved in a 1:1 mixture of pyridine and acetic anhydride (10 ml)
and was left to stir overnight, at which point the solution was
evaporated to dryness followed by trituration of the resulting oil
with toluene (2  5 ml) (quantitative hydroxyl group protec-
tion). Without further purification, the O-acetyl protected
material (125 mg, 0.34 mmol) was dissolved in N,N-dim-
ethylformamide dimethyl acetal (5 ml) and was refluxed, under
argon, at 115 °C for 24 h. After refluxing, the solution was
cooled and evaporated to dryness in vacuo. In a separate recep-
tacle, 50 – 60% hydrazine hydrate solution (8 eq, 85 l) was
added slowly (dropwise) to acetic acid (8 ml). This solution
was then rapidly transferred to the dried intermediate and was
refluxed at 95 °C for 15 h. After reflux, the solution was cooled
and evaporated to dryness in vacuo. The crude material was dry
loaded onto silica and was directly purified by Flash Chroma-
tography (heptane/ethyl acetate3 ethyl acetate). Eluted frac-
tions were analyzed by LC-MS and appropriately combined and
evaporated to dryness, resulting in a white foam (85 mg, 48%
yield). The resulting 1,2,4-triazole (40 mg, 0.10 mmol) was then
O-acetyl deprotected using a 1:1 solution of 1,4-dioxane and 1.5
M aqueous sodium hydroxide (pH 10). The reaction was mon-
itored by TLC and on completion, the basic solution was neu-
tralized using Amberlite IR-120 H ion-exchange resin. The
resin was rinsed and the resulting solution was lyophilized. The
lyophilized material was then purified by Flash Chromatogra-
phy (2 g silica; gradient elution, 1:1 ethyl acetate/heptane 3
ethyl acetate 3 3:1 ethyl acetate/methanol). Eluted fractions
were analyzed by LC-MS and appropriately combined and
evaporated to dryness (20 mg, 63% yield; Rf 0.41, ethyl acetate),
with an overall yield of 9% yield over five steps: 1H NMR (500
MHz, MeOH-D4):   8.34 (br, s, 1 H), 6.88 (s, 2 H), 3.76 (t, J 
6.0 Hz, 4 H), 3.58 (t, J  6.0 Hz, 4 H). 13C NMR (101 MHz,
MeOH-D4):   153.21–151.14 (br, s), 144.66, 137.53, 133.52,
112.14, 59.95, 54.58. HRMS-TOF: Theo. m/z 317.0567; obs. m/z
317.0573; [MH], C12H15Cl2N4O2.
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